Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Dartmouth-Hitchcock Medical Center |
---|---|
Information provided by: | Dartmouth-Hitchcock Medical Center |
ClinicalTrials.gov Identifier: | NCT00689884 |
The purpose of this study is to determine the efficacy of Pegfilgrastim in the mobilization of autologous peripheral blood stem cells (PBSCs), defined as cell yield ≥ 3 x 10e6 CD34+/kg and to assess the costs related to Pegfilgrastim use in the mobilization of autologous PBSCs. Also to determine the side effects of Pegfilgrastim in the mobilization of autologous peripheral blood stem cells.
Condition | Intervention |
---|---|
Hematologic Malignancies |
Drug: Pegfilgrastim |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Prospective Feasibility and Cost Analysis of Peripheral Blood Stem Cell Mobilization Using Pegfilgrastim in Patients With Hematologic Malignancies |
Estimated Enrollment: | 9 |
Study Start Date: | January 2007 |
Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, New Hampshire | |
Dartmouth-Hitchcock Medical Center | |
Lebanon, New Hampshire, United States, 03756 |
Principal Investigator: | John M Hill Jr., MD | Dartmouth-Hitchcock Medical Center |
Responsible Party: | Dartmouth-Hitchcock Medical Center ( Dr.John Hill Jr., MD ) |
Study ID Numbers: | D0546 |
Study First Received: | May 30, 2008 |
Last Updated: | October 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00689884 |
Health Authority: | United States: Institutional Review Board |
Hematologic Neoplasms Hematologic Diseases |
Neoplasms Neoplasms by Site |